E-LIB Suche - Ergebnisse für: Landsburg, D. J.

1

Outcomes of diffuse large/high grade B cell lymphoma patien..:

Landsburg, D. J. ; Nasta, S. D. ; Svoboda, J....
Hematological Oncology. 41 (2023) S2 - p. 448-449 , 2023

Link: https://doi.org/10.1002/..

2

Combination of everolimus and itacitinib in patients with H..:

Svoboda, J. ; Landsburg, D. L. ; Nasta, S. D....
Hematological Oncology. 41 (2023) S2 - p. 594-595 , 2023

Link: https://doi.org/10.1002/..

3

Outcomes with bendamustine lymphodepletion and brexucabtage..:

Chong, E. A. ; Gerson, J. N. ; Nasta, S. D....
Hematological Oncology. 41 (2023) S2 - p. 528-529 , 2023

Link: https://doi.org/10.1002/..

4

BENDAMUSTINE LYMPHODEPLETION TRIGGERS REDUCED INFLAMMATORY ..:

Ghilardi, G. ; Paruzzo, L. ; Svoboda, J....
Hematological Oncology. 41 (2023) S2 - p. 201-201 , 2023

Link: https://doi.org/10.1002/..

5

FOURTH GENERATION HUCART19‐IL18 PRODUCES DURABLE RESPONSES ..:

Svoboda, J. ; Landsburg, D. L. ; Chong, E. A....
Hematological Oncology. 41 (2023) S2 - p. 35-37 , 2023

Link: https://doi.org/10.1002/..

6

Brentuximab vedotin (BV) + AVD for newly diagnosed classic ..:

Bowers, J. T. ; Anna, J. ; Bair, S. M....
Hematological Oncology. 41 (2023) S2 - p. 359-360 , 2023

Link: https://doi.org/10.1002/..

7

Predictors of long‐term survival outcomes following receipt..:

Landsburg, D. J. ; Nasta, S. D. ; Svoboda, J....
Hematological Oncology. 41 (2023) S2 - p. 445-447 , 2023

Link: https://doi.org/10.1002/..

8

P1152: RESULTS FROM A PHASE I PHARMACOKINETIC (PK) AND SAFE..:

Hernandez-Ilizaliturri, F. J. ; Kuruvilla, J. ; Christian, B. A....
HemaSphere. 6 (2022) - p. 1039-1040 , 2022

Link: https://doi.org/10.1097/..

9

Cytokine Release Syndrome and Neurotoxicity after Chimeric ..:

Yegya-Raman, N. ; Wright, C.M. ; Zhang, S....
International Journal of Radiation Oncology*Biology*Physics. 114 (2022) 3 - p. S84-S85 , 2022

Link: https://doi.org/10.1016/..

10

TIME‐TO‐RESPONSE FOR PATIENTS WITH RELAPSED/REFRACTORY AGGR..:

Hughes, M. E. ; Nasta, S. D. ; Gerson, J. N....
Hematological Oncology. 39 (2021) S2 - p. , 2021

Link: https://doi.org/10.1002/..

11

SURVIVAL FOLLOWING FIRST RELAPSE IN YOUNGER PATIENTS WITH M..:

Karmali, R. ; Donovan, A. ; Wagner‐Johntson, N....
Hematological Oncology. 39 (2021) S2 - p. , 2021

Link: https://doi.org/10.1002/..

12

Radiation Therapy (RT)-Based Salvage Therapy for Classical ..:

Manjunath, S.H. ; Larose, M.I. ; Carpenter, M....
International Journal of Radiation Oncology*Biology*Physics. 111 (2021) 3 - p. e305 , 2021

Link: https://doi.org/10.1016/..

13

REAL WORLD OUTCOMES OF OBINUTUZUMAB MONOTHERAPY IN PATIENTS..:

Hughes, M.E. ; Suen, C. ; Namoglu, E....
Hematological Oncology. 37 (2019) S2 - p. 378-379 , 2019

Link: https://doi.org/10.1002/..

14

DOSE FINDING STUDY TO ASSESS SAFETY, PK AND EFFICACY OF FIM..:

Younes, A. ; Batlevi, C.L. ; Cohen, J.B....
Hematological Oncology. 37 (2019) S2 - p. 561-562 , 2019

Link: https://doi.org/10.1002/..

15

CD19‐DIRECTED CAR T CELL THERAPY (CTL019) FOR RELAPSED/REFR..:

Chong, E.A. ; Svoboda, J. ; Nasta, S.D....
Hematological Oncology. 37 (2019) S2 - p. 137-138 , 2019

Link: https://doi.org/10.1002/..